Altimmune Inc (NASDAQ:ALT)
| 4.87 Delayed Data As of 3:59pm ET |  +0.25 / +5.41%Today’s Change | 3.83 Today|||52-Week Range 19.46 | -46.83% Year-to-Date |
Latest ALT News | Press Releases
| Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High? May 23 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 4.62 |
| Today’s open | 4.62 |
| Day’s range | 4.62 - 4.94 |
| Volume | 38,815 |
| Average volume (3 months) | 807,446 |
| Market cap | $206.2M |
Data as of 3:59pm ET, 05/26/2022
Growth & Valuation
| Earnings growth (last year) | -22.94% |
| Earnings growth (this year) | +4.32% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -46.12% |
| P/E ratio | NM |
| Price/Sales | 85.74 |
| Price/Book | 1.04 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| KMDAKamada Ltd | +0.08 | +1.90% |
| JNCEJounce Therapeutics ... | +0.08 | +2.19% |
| XOMAXOMA Corp | +0.84 | +4.89% |
| LCTXLineage Cell Therape... | +0.04 | +3.28% |
Data as of 4:00pm ET, 05/26/2022
Financials
| Next reporting date | August 16, 2022 |
| EPS forecast (this quarter) | -$0.48 |
| Annual revenue (last year) | $4.4M |
| Annual profit (last year) | -$97.1M |
| Net profit margin | -2,201.43% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Gaithersburg, Maryland |
Forecasts
